$0.390000
At close: Nov 18, 3:56 PM EDT
Comments
Loading...
Latest news for Seelos Therapeutics Inc COM PAR NEW $0.001 (OTC:SEEL) Stock
Seelos Therapeutics Inc COM PAR NEW $0.001 Stock (OTC: SEEL)
Categories: All
Tuesday, October 15, 2024
- Nasdaq Down 150 Points; Johnson & Johnson Reports Better-Than-Expected Q3 Results
- Seelos Therapeutics Delisted From Nasdaq, Will Transition To OTC Market
- 12 Health Care Stocks Moving In Tuesday's Intraday Session
- Crude Oil Tumbles 5%; Goldman Sachs Earnings Top Views
- Seelos Therapeutics shares are trading lower ...
- Dow Dips 200 Points; Bank of America Posts Upbeat Earnings
- Seelos Therapeutics Says On Oct. 14 Received ...
Friday, September 27, 2024
Thursday, September 26, 2024
Wednesday, September 25, 2024
Tuesday, September 24, 2024
- Crude Oil Gains Over 1%; BioVie Shares Plunge
- What's Going On With Seelos Therapeutics Stock Tuesday?
- Nasdaq Surges 100 Points; Thor Industries Earnings Top Views
- Dow Rises Over 50 Points; AutoZone Posts Downbeat Earnings
- Seelos Therapeutics shares are trading higher...
- Seelos Therapeutics Signs Material Transfer A...
Monday, September 23, 2024
Monday, August 19, 2024
Friday, August 16, 2024
Wednesday, July 31, 2024
Friday, July 26, 2024
Tuesday, July 16, 2024
Wednesday, July 10, 2024
Wednesday, June 12, 2024
Friday, June 07, 2024
Friday, May 17, 2024
Wednesday, May 15, 2024
Tuesday, May 14, 2024
Tuesday, May 07, 2024
Friday, May 03, 2024
Monday, April 29, 2024
Wednesday, March 20, 2024
Tuesday, March 19, 2024
- Nasdaq Turns Higher; Caleres Posts Upbeat Q4 Results
- Why Peraso Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
- 12 Health Care Stocks Moving In Tuesday's Intraday Session
- Dow Jumps 200 Points; Core & Main Shares Gain After Q4 Results
- Nasdaq Down 100 Points; US Housing Starts Surge In February
- CNS Disorder-Focused Seelos Therapeutics Plunges To 52-Week Low - Here's Why
- Seelos Therapeutics shares are trading lower ...
- 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- Seelos Therapeutics Says The Study Did Not Me...